nodes	percent_of_prediction	percent_of_DWPC	metapath
Quinidine barbiturate—GRIA2—amyotrophic lateral sclerosis	0.492	1	CbGaD
Quinidine barbiturate—SCN5A—Riluzole—amyotrophic lateral sclerosis	0.374	1	CbGbCtD
Quinidine barbiturate—Disseminated intravascular coagulation—Riluzole—amyotrophic lateral sclerosis	0.00303	0.0352	CcSEcCtD
Quinidine barbiturate—Hypoventilation—Riluzole—amyotrophic lateral sclerosis	0.0029	0.0338	CcSEcCtD
Quinidine barbiturate—CNS depression NOS—Riluzole—amyotrophic lateral sclerosis	0.00263	0.0307	CcSEcCtD
Quinidine barbiturate—KCNK1—hindbrain—amyotrophic lateral sclerosis	0.00252	0.085	CbGeAlD
Quinidine barbiturate—Thrombocytopenic purpura—Riluzole—amyotrophic lateral sclerosis	0.0023	0.0268	CcSEcCtD
Quinidine barbiturate—GRIA2—hindbrain—amyotrophic lateral sclerosis	0.00205	0.0692	CbGeAlD
Quinidine barbiturate—Hypothermia—Riluzole—amyotrophic lateral sclerosis	0.00193	0.0225	CcSEcCtD
Quinidine barbiturate—Body temperature decreased—Riluzole—amyotrophic lateral sclerosis	0.00193	0.0225	CcSEcCtD
Quinidine barbiturate—Completed suicide—Riluzole—amyotrophic lateral sclerosis	0.00184	0.0214	CcSEcCtD
Quinidine barbiturate—Myasthenia—Riluzole—amyotrophic lateral sclerosis	0.00172	0.02	CcSEcCtD
Quinidine barbiturate—Hypoxia—Riluzole—amyotrophic lateral sclerosis	0.0017	0.0198	CcSEcCtD
Quinidine barbiturate—KCNK1—brainstem—amyotrophic lateral sclerosis	0.00144	0.0487	CbGeAlD
Quinidine barbiturate—Pulmonary function test decreased—Riluzole—amyotrophic lateral sclerosis	0.00143	0.0167	CcSEcCtD
Quinidine barbiturate—Respiratory depression—Riluzole—amyotrophic lateral sclerosis	0.00143	0.0167	CcSEcCtD
Quinidine barbiturate—Ventricular fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00141	0.0164	CcSEcCtD
Quinidine barbiturate—GABRA2—hindbrain—amyotrophic lateral sclerosis	0.00133	0.045	CbGeAlD
Quinidine barbiturate—Petechiae—Riluzole—amyotrophic lateral sclerosis	0.00131	0.0153	CcSEcCtD
Quinidine barbiturate—GABRA1—hindbrain—amyotrophic lateral sclerosis	0.00129	0.0435	CbGeAlD
Quinidine barbiturate—Liver injury—Riluzole—amyotrophic lateral sclerosis	0.00128	0.015	CcSEcCtD
Quinidine barbiturate—GRIA2—embryo—amyotrophic lateral sclerosis	0.00128	0.0433	CbGeAlD
Quinidine barbiturate—Apnoea—Riluzole—amyotrophic lateral sclerosis	0.00127	0.0148	CcSEcCtD
Quinidine barbiturate—Delirium—Riluzole—amyotrophic lateral sclerosis	0.00126	0.0146	CcSEcCtD
Quinidine barbiturate—Bone disorder—Riluzole—amyotrophic lateral sclerosis	0.0012	0.0139	CcSEcCtD
Quinidine barbiturate—Ventricular extrasystoles—Riluzole—amyotrophic lateral sclerosis	0.0012	0.0139	CcSEcCtD
Quinidine barbiturate—Thinking abnormal—Riluzole—amyotrophic lateral sclerosis	0.00118	0.0137	CcSEcCtD
Quinidine barbiturate—GRIA2—brainstem—amyotrophic lateral sclerosis	0.00118	0.0397	CbGeAlD
Quinidine barbiturate—Respiratory failure—Riluzole—amyotrophic lateral sclerosis	0.0011	0.0128	CcSEcCtD
Quinidine barbiturate—Phenobarbital—GRIA2—amyotrophic lateral sclerosis	0.00108	1	CrCbGaD
Quinidine barbiturate—Ventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00108	0.0126	CcSEcCtD
Quinidine barbiturate—Hepatocellular injury—Riluzole—amyotrophic lateral sclerosis	0.00108	0.0126	CcSEcCtD
Quinidine barbiturate—Injection site reaction—Riluzole—amyotrophic lateral sclerosis	0.00107	0.0125	CcSEcCtD
Quinidine barbiturate—Dermatitis contact—Riluzole—amyotrophic lateral sclerosis	0.00107	0.0124	CcSEcCtD
Quinidine barbiturate—GRIA2—Unblocking of NMDA receptor, glutamate binding and activation—NEFL—amyotrophic lateral sclerosis	0.00105	0.0585	CbGpPWpGaD
Quinidine barbiturate—Depressed level of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00104	0.0122	CcSEcCtD
Quinidine barbiturate—Photophobia—Riluzole—amyotrophic lateral sclerosis	0.00101	0.0118	CcSEcCtD
Quinidine barbiturate—Aplastic anaemia—Riluzole—amyotrophic lateral sclerosis	0.00101	0.0118	CcSEcCtD
Quinidine barbiturate—KCNK1—medulla oblongata—amyotrophic lateral sclerosis	0.00101	0.034	CbGeAlD
Quinidine barbiturate—Coma—Riluzole—amyotrophic lateral sclerosis	0.000987	0.0115	CcSEcCtD
Quinidine barbiturate—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.000977	0.0114	CcSEcCtD
Quinidine barbiturate—Pulmonary oedema—Riluzole—amyotrophic lateral sclerosis	0.000962	0.0112	CcSEcCtD
Quinidine barbiturate—Mental disability—Riluzole—amyotrophic lateral sclerosis	0.000938	0.0109	CcSEcCtD
Quinidine barbiturate—KCNK1—Potassium Channels—KCNJ10—amyotrophic lateral sclerosis	0.000918	0.0514	CbGpPWpGaD
Quinidine barbiturate—KCNK1—spinal cord—amyotrophic lateral sclerosis	0.000898	0.0303	CbGeAlD
Quinidine barbiturate—Photosensitivity—Riluzole—amyotrophic lateral sclerosis	0.000893	0.0104	CcSEcCtD
Quinidine barbiturate—Deafness—Riluzole—amyotrophic lateral sclerosis	0.000877	0.0102	CcSEcCtD
Quinidine barbiturate—Eczema—Riluzole—amyotrophic lateral sclerosis	0.000873	0.0102	CcSEcCtD
Quinidine barbiturate—Dermatitis exfoliative—Riluzole—amyotrophic lateral sclerosis	0.000831	0.00968	CcSEcCtD
Quinidine barbiturate—Purpura—Riluzole—amyotrophic lateral sclerosis	0.000814	0.00948	CcSEcCtD
Quinidine barbiturate—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.000784	0.00914	CcSEcCtD
Quinidine barbiturate—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.000772	0.00899	CcSEcCtD
Quinidine barbiturate—GABRA2—brainstem—amyotrophic lateral sclerosis	0.000764	0.0258	CbGeAlD
Quinidine barbiturate—KCNK1—nervous system—amyotrophic lateral sclerosis	0.000757	0.0255	CbGeAlD
Quinidine barbiturate—Cardiac arrest—Riluzole—amyotrophic lateral sclerosis	0.000746	0.00869	CcSEcCtD
Quinidine barbiturate—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.000743	0.00865	CcSEcCtD
Quinidine barbiturate—GABRA1—brainstem—amyotrophic lateral sclerosis	0.000738	0.0249	CbGeAlD
Quinidine barbiturate—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.000737	0.00859	CcSEcCtD
Quinidine barbiturate—GRIA2—spinal cord—amyotrophic lateral sclerosis	0.000731	0.0247	CbGeAlD
Quinidine barbiturate—KCNK1—central nervous system—amyotrophic lateral sclerosis	0.000728	0.0246	CbGeAlD
Quinidine barbiturate—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.000724	0.00843	CcSEcCtD
Quinidine barbiturate—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.000716	0.00834	CcSEcCtD
Quinidine barbiturate—KCNK1—cerebellum—amyotrophic lateral sclerosis	0.000712	0.024	CbGeAlD
Quinidine barbiturate—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.000709	0.00826	CcSEcCtD
Quinidine barbiturate—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.000692	0.00806	CcSEcCtD
Quinidine barbiturate—Asthma—Riluzole—amyotrophic lateral sclerosis	0.000678	0.0079	CcSEcCtD
Quinidine barbiturate—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.00066	0.00769	CcSEcCtD
Quinidine barbiturate—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.000644	0.0075	CcSEcCtD
Quinidine barbiturate—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.000634	0.00738	CcSEcCtD
Quinidine barbiturate—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.000619	0.00721	CcSEcCtD
Quinidine barbiturate—GRIA2—nervous system—amyotrophic lateral sclerosis	0.000616	0.0208	CbGeAlD
Quinidine barbiturate—GRIA2—central nervous system—amyotrophic lateral sclerosis	0.000593	0.02	CbGeAlD
Quinidine barbiturate—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.000589	0.00686	CcSEcCtD
Quinidine barbiturate—GRIA2—cerebellum—amyotrophic lateral sclerosis	0.00058	0.0196	CbGeAlD
Quinidine barbiturate—Sweating—Riluzole—amyotrophic lateral sclerosis	0.000579	0.00675	CcSEcCtD
Quinidine barbiturate—KCNK1—brain—amyotrophic lateral sclerosis	0.000578	0.0195	CbGeAlD
Quinidine barbiturate—GRIA2—N-cadherin signaling events—DCTN1—amyotrophic lateral sclerosis	0.000574	0.0321	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.000564	0.019	CbGeAlD
Quinidine barbiturate—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.000564	0.00657	CcSEcCtD
Quinidine barbiturate—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.000552	0.00643	CcSEcCtD
Quinidine barbiturate—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.000545	0.00635	CcSEcCtD
Quinidine barbiturate—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.000543	0.00632	CcSEcCtD
Quinidine barbiturate—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.000543	0.00632	CcSEcCtD
Quinidine barbiturate—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.00054	0.00629	CcSEcCtD
Quinidine barbiturate—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.000536	0.00624	CcSEcCtD
Quinidine barbiturate—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.000532	0.0062	CcSEcCtD
Quinidine barbiturate—GRIA2—Activation of NMDA receptor upon glutamate binding and postsynaptic events—NEFL—amyotrophic lateral sclerosis	0.000517	0.029	CbGpPWpGaD
Quinidine barbiturate—GABRA1—medulla oblongata—amyotrophic lateral sclerosis	0.000515	0.0174	CbGeAlD
Quinidine barbiturate—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.000513	0.00598	CcSEcCtD
Quinidine barbiturate—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.000507	0.00591	CcSEcCtD
Quinidine barbiturate—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.000504	0.00587	CcSEcCtD
Quinidine barbiturate—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00049	0.00571	CcSEcCtD
Quinidine barbiturate—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000489	0.0057	CcSEcCtD
Quinidine barbiturate—Chills—Riluzole—amyotrophic lateral sclerosis	0.000487	0.00567	CcSEcCtD
Quinidine barbiturate—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.000475	0.00554	CcSEcCtD
Quinidine barbiturate—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.000472	0.0055	CcSEcCtD
Quinidine barbiturate—GRIA2—brain—amyotrophic lateral sclerosis	0.000471	0.0159	CbGeAlD
Quinidine barbiturate—Tension—Riluzole—amyotrophic lateral sclerosis	0.000463	0.0054	CcSEcCtD
Quinidine barbiturate—GABRA1—spinal cord—amyotrophic lateral sclerosis	0.000459	0.0155	CbGeAlD
Quinidine barbiturate—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.000459	0.00534	CcSEcCtD
Quinidine barbiturate—SCN5A—nervous system—amyotrophic lateral sclerosis	0.000452	0.0152	CbGeAlD
Quinidine barbiturate—Tremor—Riluzole—amyotrophic lateral sclerosis	0.000443	0.00515	CcSEcCtD
Quinidine barbiturate—SCN5A—central nervous system—amyotrophic lateral sclerosis	0.000435	0.0147	CbGeAlD
Quinidine barbiturate—Agitation—Riluzole—amyotrophic lateral sclerosis	0.000434	0.00506	CcSEcCtD
Quinidine barbiturate—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.000432	0.00503	CcSEcCtD
Quinidine barbiturate—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.000424	0.00494	CcSEcCtD
Quinidine barbiturate—Syncope—Riluzole—amyotrophic lateral sclerosis	0.000424	0.00493	CcSEcCtD
Quinidine barbiturate—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.000423	0.00492	CcSEcCtD
Quinidine barbiturate—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.000417	0.00486	CcSEcCtD
Quinidine barbiturate—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.000415	0.00484	CcSEcCtD
Quinidine barbiturate—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.000409	0.00477	CcSEcCtD
Quinidine barbiturate—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.000402	0.00468	CcSEcCtD
Quinidine barbiturate—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.000402	0.00468	CcSEcCtD
Quinidine barbiturate—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.000402	0.00468	CcSEcCtD
Quinidine barbiturate—KCNK1—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.000401	0.0224	CbGpPWpGaD
Quinidine barbiturate—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.000401	0.00467	CcSEcCtD
Quinidine barbiturate—GABRA2—nervous system—amyotrophic lateral sclerosis	0.0004	0.0135	CbGeAlD
Quinidine barbiturate—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.000399	0.00465	CcSEcCtD
Quinidine barbiturate—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.000389	0.00453	CcSEcCtD
Quinidine barbiturate—GABRA1—nervous system—amyotrophic lateral sclerosis	0.000387	0.0131	CbGeAlD
Quinidine barbiturate—Oedema—Riluzole—amyotrophic lateral sclerosis	0.000385	0.00449	CcSEcCtD
Quinidine barbiturate—GABRA2—central nervous system—amyotrophic lateral sclerosis	0.000385	0.013	CbGeAlD
Quinidine barbiturate—CHRM2—nervous system—amyotrophic lateral sclerosis	0.000385	0.013	CbGeAlD
Quinidine barbiturate—Shock—Riluzole—amyotrophic lateral sclerosis	0.000379	0.00442	CcSEcCtD
Quinidine barbiturate—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.000378	0.0044	CcSEcCtD
Quinidine barbiturate—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.000377	0.0044	CcSEcCtD
Quinidine barbiturate—GABRA2—cerebellum—amyotrophic lateral sclerosis	0.000377	0.0127	CbGeAlD
Quinidine barbiturate—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.000376	0.00438	CcSEcCtD
Quinidine barbiturate—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.000374	0.00436	CcSEcCtD
Quinidine barbiturate—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.000373	0.00434	CcSEcCtD
Quinidine barbiturate—GABRA1—central nervous system—amyotrophic lateral sclerosis	0.000372	0.0126	CbGeAlD
Quinidine barbiturate—CHRM2—central nervous system—amyotrophic lateral sclerosis	0.00037	0.0125	CbGeAlD
Quinidine barbiturate—KCNK1—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.00037	0.0207	CbGpPWpGaD
Quinidine barbiturate—KCNH2—medulla oblongata—amyotrophic lateral sclerosis	0.00037	0.0125	CbGeAlD
Quinidine barbiturate—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.000367	0.00428	CcSEcCtD
Quinidine barbiturate—GABRA2—GABA receptor activation—KCNJ10—amyotrophic lateral sclerosis	0.000364	0.0204	CbGpPWpGaD
Quinidine barbiturate—GABRA1—cerebellum—amyotrophic lateral sclerosis	0.000364	0.0123	CbGeAlD
Quinidine barbiturate—GRIA2—BDNF signaling pathway—PTPRF—amyotrophic lateral sclerosis	0.000361	0.0202	CbGpPWpGaD
Quinidine barbiturate—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00036	0.0042	CcSEcCtD
Quinidine barbiturate—KCNK1—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.000357	0.02	CbGpPWpGaD
Quinidine barbiturate—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000351	0.00409	CcSEcCtD
Quinidine barbiturate—SCN5A—brain—amyotrophic lateral sclerosis	0.000345	0.0117	CbGeAlD
Quinidine barbiturate—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000344	0.004	CcSEcCtD
Quinidine barbiturate—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.000343	0.00399	CcSEcCtD
Quinidine barbiturate—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000335	0.0039	CcSEcCtD
Quinidine barbiturate—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000333	0.00388	CcSEcCtD
Quinidine barbiturate—KCNH2—spinal cord—amyotrophic lateral sclerosis	0.00033	0.0111	CbGeAlD
Quinidine barbiturate—Pain—Riluzole—amyotrophic lateral sclerosis	0.00033	0.00384	CcSEcCtD
Quinidine barbiturate—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00033	0.00384	CcSEcCtD
Quinidine barbiturate—KCNK1—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.000327	0.0183	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.000323	0.0109	CbGeAlD
Quinidine barbiturate—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.000318	0.0037	CcSEcCtD
Quinidine barbiturate—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000315	0.00367	CcSEcCtD
Quinidine barbiturate—GABRA1—GABA receptor activation—KCNJ10—amyotrophic lateral sclerosis	0.00031	0.0174	CbGpPWpGaD
Quinidine barbiturate—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.000306	0.00357	CcSEcCtD
Quinidine barbiturate—GABRA2—brain—amyotrophic lateral sclerosis	0.000306	0.0103	CbGeAlD
Quinidine barbiturate—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000305	0.00355	CcSEcCtD
Quinidine barbiturate—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000305	0.00355	CcSEcCtD
Quinidine barbiturate—KCNK1—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.000304	0.017	CbGpPWpGaD
Quinidine barbiturate—KCNK1—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.000304	0.017	CbGpPWpGaD
Quinidine barbiturate—GABRA1—brain—amyotrophic lateral sclerosis	0.000296	0.00998	CbGeAlD
Quinidine barbiturate—CHRM2—brain—amyotrophic lateral sclerosis	0.000294	0.00992	CbGeAlD
Quinidine barbiturate—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000284	0.00331	CcSEcCtD
Quinidine barbiturate—CYP2D6—Melatonin metabolism and effects—ECE1—amyotrophic lateral sclerosis	0.000279	0.0156	CbGpPWpGaD
Quinidine barbiturate—KCNH2—nervous system—amyotrophic lateral sclerosis	0.000278	0.00938	CbGeAlD
Quinidine barbiturate—KCNH2—Potassium Channels—KCNJ10—amyotrophic lateral sclerosis	0.000277	0.0155	CbGpPWpGaD
Quinidine barbiturate—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000277	0.00322	CcSEcCtD
Quinidine barbiturate—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000273	0.00318	CcSEcCtD
Quinidine barbiturate—KCNK1—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.000271	0.0151	CbGpPWpGaD
Quinidine barbiturate—KCNH2—central nervous system—amyotrophic lateral sclerosis	0.000268	0.00903	CbGeAlD
Quinidine barbiturate—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000264	0.00307	CcSEcCtD
Quinidine barbiturate—KCNH2—cerebellum—amyotrophic lateral sclerosis	0.000261	0.00882	CbGeAlD
Quinidine barbiturate—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000255	0.00297	CcSEcCtD
Quinidine barbiturate—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000245	0.00285	CcSEcCtD
Quinidine barbiturate—Rash—Riluzole—amyotrophic lateral sclerosis	0.000243	0.00283	CcSEcCtD
Quinidine barbiturate—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000243	0.00283	CcSEcCtD
Quinidine barbiturate—Headache—Riluzole—amyotrophic lateral sclerosis	0.000241	0.00281	CcSEcCtD
Quinidine barbiturate—GRIA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—KCNJ10—amyotrophic lateral sclerosis	0.000238	0.0133	CbGpPWpGaD
Quinidine barbiturate—SCN5A—SIDS Susceptibility Pathways—ECE1—amyotrophic lateral sclerosis	0.000234	0.0131	CbGpPWpGaD
Quinidine barbiturate—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000229	0.00267	CcSEcCtD
Quinidine barbiturate—KCNH2—SIDS Susceptibility Pathways—ECE1—amyotrophic lateral sclerosis	0.000226	0.0127	CbGpPWpGaD
Quinidine barbiturate—KCNH2—brain—amyotrophic lateral sclerosis	0.000212	0.00717	CbGeAlD
Quinidine barbiturate—GABRA2—Ion channel transport—TRPM7—amyotrophic lateral sclerosis	0.000206	0.0115	CbGpPWpGaD
Quinidine barbiturate—GRIA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—NEFL—amyotrophic lateral sclerosis	0.000194	0.0108	CbGpPWpGaD
Quinidine barbiturate—GRIA2—Transmission across Chemical Synapses—KCNJ10—amyotrophic lateral sclerosis	0.000179	0.01	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Ion channel transport—TRPM7—amyotrophic lateral sclerosis	0.000176	0.00983	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.000169	0.00572	CbGeAlD
Quinidine barbiturate—GABRA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—KCNJ10—amyotrophic lateral sclerosis	0.000167	0.00936	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.000163	0.00551	CbGeAlD
Quinidine barbiturate—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.000159	0.00538	CbGeAlD
Quinidine barbiturate—GRIA2—Transmission across Chemical Synapses—SLC1A2—amyotrophic lateral sclerosis	0.000159	0.00891	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GRIA2—amyotrophic lateral sclerosis	0.000154	0.00864	CbGpPWpGaD
Quinidine barbiturate—GABRA1—SIDS Susceptibility Pathways—ECE1—amyotrophic lateral sclerosis	0.000154	0.00861	CbGpPWpGaD
Quinidine barbiturate—GRIA2—BDNF signaling pathway—MAPT—amyotrophic lateral sclerosis	0.000153	0.00857	CbGpPWpGaD
Quinidine barbiturate—SCN5A—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	0.000151	0.00842	CbGpPWpGaD
Quinidine barbiturate—SCN5A—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	0.000151	0.00842	CbGpPWpGaD
Quinidine barbiturate—SCN5A—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	0.000151	0.00842	CbGpPWpGaD
Quinidine barbiturate—KCNH2—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	0.000146	0.00816	CbGpPWpGaD
Quinidine barbiturate—KCNH2—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	0.000146	0.00816	CbGpPWpGaD
Quinidine barbiturate—KCNH2—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	0.000146	0.00816	CbGpPWpGaD
Quinidine barbiturate—GRIA2—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	0.000146	0.00815	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—KCNJ10—amyotrophic lateral sclerosis	0.000143	0.00798	CbGpPWpGaD
Quinidine barbiturate—GRIA2—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.000137	0.00766	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—NEFL—amyotrophic lateral sclerosis	0.000136	0.00763	CbGpPWpGaD
Quinidine barbiturate—GRIA2—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	0.000135	0.00757	CbGpPWpGaD
Quinidine barbiturate—GRIA2—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	0.000135	0.00757	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GRIA2—amyotrophic lateral sclerosis	0.000132	0.00737	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—brain—amyotrophic lateral sclerosis	0.00013	0.00437	CbGeAlD
Quinidine barbiturate—GABRA2—Transmission across Chemical Synapses—KCNJ10—amyotrophic lateral sclerosis	0.000126	0.00704	CbGpPWpGaD
Quinidine barbiturate—GRIA2—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.000122	0.00683	CbGpPWpGaD
Quinidine barbiturate—GRIA2—BDNF signaling pathway—SQSTM1—amyotrophic lateral sclerosis	0.000121	0.00677	CbGpPWpGaD
Quinidine barbiturate—KCNH2—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.000121	0.00676	CbGpPWpGaD
Quinidine barbiturate—GRIA2—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.000121	0.00675	CbGpPWpGaD
Quinidine barbiturate—CHRM2—SIDS Susceptibility Pathways—ECE1—amyotrophic lateral sclerosis	0.00012	0.00674	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Cardiac Progenitor Differentiation—IGF1—amyotrophic lateral sclerosis	0.00012	0.00671	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—NEFL—amyotrophic lateral sclerosis	0.000116	0.00651	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Transmission across Chemical Synapses—GRIA2—amyotrophic lateral sclerosis	0.000116	0.0065	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Transmission across Chemical Synapses—SLC1A2—amyotrophic lateral sclerosis	0.000112	0.00627	CbGpPWpGaD
Quinidine barbiturate—GRIA2—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.000112	0.00624	CbGpPWpGaD
Quinidine barbiturate—KCNH2—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.000112	0.00624	CbGpPWpGaD
Quinidine barbiturate—KCNH2—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.000108	0.00603	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Transmission across Chemical Synapses—KCNJ10—amyotrophic lateral sclerosis	0.000107	0.006	CbGpPWpGaD
Quinidine barbiturate—GRIA2—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.000104	0.0058	CbGpPWpGaD
Quinidine barbiturate—GRIA2—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.000104	0.0058	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	0.000103	0.00574	CbGpPWpGaD
Quinidine barbiturate—GABRA1—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	9.92e-05	0.00555	CbGpPWpGaD
Quinidine barbiturate—GABRA1—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	9.92e-05	0.00555	CbGpPWpGaD
Quinidine barbiturate—GABRA1—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	9.92e-05	0.00555	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Transmission across Chemical Synapses—GRIA2—amyotrophic lateral sclerosis	9.9e-05	0.00554	CbGpPWpGaD
Quinidine barbiturate—KCNH2—Neuronal System—NEFL—amyotrophic lateral sclerosis	9.86e-05	0.00551	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	9.64e-05	0.00539	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Transmission across Chemical Synapses—SLC1A2—amyotrophic lateral sclerosis	9.56e-05	0.00535	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Axon guidance—PFN1—amyotrophic lateral sclerosis	9.55e-05	0.00535	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	9.53e-05	0.00533	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	9.53e-05	0.00533	CbGpPWpGaD
Quinidine barbiturate—GRIA2—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	9.25e-05	0.00517	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Regulation of Actin Cytoskeleton—PFN1—amyotrophic lateral sclerosis	9.17e-05	0.00513	CbGpPWpGaD
Quinidine barbiturate—KCNH2—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	9.16e-05	0.00513	CbGpPWpGaD
Quinidine barbiturate—KCNH2—Neuronal System—CHAT—amyotrophic lateral sclerosis	9.16e-05	0.00513	CbGpPWpGaD
Quinidine barbiturate—GRIA2—BDNF signaling pathway—BDNF—amyotrophic lateral sclerosis	9.11e-05	0.0051	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Neuronal System—GRIA2—amyotrophic lateral sclerosis	8.9e-05	0.00498	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	8.74e-05	0.00489	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	8.59e-05	0.00481	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	8.5e-05	0.00475	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	8.22e-05	0.0046	CbGpPWpGaD
Quinidine barbiturate—KCNH2—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	8.17e-05	0.00457	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	8.13e-05	0.00455	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	8.13e-05	0.00455	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Neuronal System—NEFL—amyotrophic lateral sclerosis	7.86e-05	0.0044	CbGpPWpGaD
Quinidine barbiturate—SCN5A—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	7.79e-05	0.00436	CbGpPWpGaD
Quinidine barbiturate—CHRM2—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	7.76e-05	0.00434	CbGpPWpGaD
Quinidine barbiturate—CHRM2—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	7.76e-05	0.00434	CbGpPWpGaD
Quinidine barbiturate—CHRM2—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	7.76e-05	0.00434	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Neuronal System—GRIA2—amyotrophic lateral sclerosis	7.59e-05	0.00424	CbGpPWpGaD
Quinidine barbiturate—KCNH2—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	7.55e-05	0.00422	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	7.33e-05	0.0041	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	7.32e-05	0.00409	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	7.31e-05	0.00409	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Neuronal System—CHAT—amyotrophic lateral sclerosis	7.31e-05	0.00409	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	7.25e-05	0.00405	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	7.17e-05	0.00401	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Developmental Biology—PFN1—amyotrophic lateral sclerosis	6.82e-05	0.00381	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Neuronal System—NEFL—amyotrophic lateral sclerosis	6.7e-05	0.00375	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	6.51e-05	0.00364	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	6.23e-05	0.00348	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Neuronal System—CHAT—amyotrophic lateral sclerosis	6.23e-05	0.00348	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	6.11e-05	0.00342	CbGpPWpGaD
Quinidine barbiturate—CHRM2—G alpha (i) signalling events—C5AR1—amyotrophic lateral sclerosis	5.59e-05	0.00313	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	5.55e-05	0.00311	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	5.21e-05	0.00291	CbGpPWpGaD
Quinidine barbiturate—GABRA1—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	5.13e-05	0.00287	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	4.62e-05	0.00258	CbGpPWpGaD
Quinidine barbiturate—GRIA2—BDNF signaling pathway—CASP3—amyotrophic lateral sclerosis	4.55e-05	0.00255	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	4.45e-05	0.00249	CbGpPWpGaD
Quinidine barbiturate—CHRM2—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	4.02e-05	0.00225	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	3.94e-05	0.0022	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	3.93e-05	0.0022	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	3.93e-05	0.0022	CbGpPWpGaD
Quinidine barbiturate—SCN5A—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	3.89e-05	0.00218	CbGpPWpGaD
Quinidine barbiturate—KCNH2—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	3.77e-05	0.00211	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	3.5e-05	0.00196	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	3.39e-05	0.00189	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	3.35e-05	0.00187	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	3.35e-05	0.00187	CbGpPWpGaD
Quinidine barbiturate—SCN5A—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	3.3e-05	0.00185	CbGpPWpGaD
Quinidine barbiturate—KCNH2—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	3.2e-05	0.00179	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	2.99e-05	0.00167	CbGpPWpGaD
Quinidine barbiturate—GABRA1—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	2.56e-05	0.00143	CbGpPWpGaD
Quinidine barbiturate—CHRM2—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	2.44e-05	0.00137	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	2.33e-05	0.0013	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	2.3e-05	0.00129	CbGpPWpGaD
Quinidine barbiturate—GABRA1—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	2.18e-05	0.00122	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Axon guidance—MMP9—amyotrophic lateral sclerosis	2.05e-05	0.00115	CbGpPWpGaD
Quinidine barbiturate—CHRM2—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	2.01e-05	0.00112	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	1.94e-05	0.00109	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	1.91e-05	0.00107	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Axon guidance—VEGFA—amyotrophic lateral sclerosis	1.84e-05	0.00103	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	1.79e-05	0.000999	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	1.79e-05	0.000999	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	1.74e-05	0.000972	CbGpPWpGaD
Quinidine barbiturate—CHRM2—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	1.7e-05	0.000953	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	1.63e-05	0.000914	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.52e-05	0.000849	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR ligand binding—C3—amyotrophic lateral sclerosis	1.48e-05	0.000827	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Developmental Biology—MMP9—amyotrophic lateral sclerosis	1.46e-05	0.000818	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	1.43e-05	0.000799	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	1.35e-05	0.000758	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.31e-05	0.000734	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	1.29e-05	0.000722	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	1.27e-05	0.000713	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—VCP—amyotrophic lateral sclerosis	1.21e-05	0.000676	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	1.17e-05	0.000654	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	1.04e-05	0.000581	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	1.03e-05	0.000574	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	9.78e-06	0.000547	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	9.03e-06	0.000505	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	8.58e-06	0.00048	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	8.35e-06	0.000467	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—C3—amyotrophic lateral sclerosis	7.59e-06	0.000424	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	7.41e-06	0.000415	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	7.05e-06	0.000395	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	6.62e-06	0.00037	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	6.3e-06	0.000353	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	5.39e-06	0.000302	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	5.07e-06	0.000284	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.48e-06	0.000251	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.17e-06	0.000233	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.98e-06	0.000223	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.66e-06	0.000205	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.45e-06	0.000193	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	3.01e-06	0.000169	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.65e-06	0.000148	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.51e-06	0.00014	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.25e-06	0.000126	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.06e-06	0.000115	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.7e-06	9.52e-05	CbGpPWpGaD
